OM
NRIX icon

Opaleye Management’s Nurix Therapeutics NRIX Stock Holding History

Opaleye Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-115,000
Closed -$1.37M – 45
2025
Q1 		$1.37M Sell
115,000
-263,500
-70% -$4.41M 0.3% 39
2024
Q4 		$7.13M Sell
378,500
-41,500
-10% -$951K 1.25% 18
2024
Q3 		$9.44M Buy
420,000
+1,072
+0.3% +$24.3K 1.57% 15
2024
Q2 		$8.74M Buy
418,928
+151,718
+57% +$2.36M 2% 14
2024
Q1 		$3.93M Buy
+267,210
New +$2.87M 0.86% 31

Other funds holding NRIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Opaleye Management's NRIX Position: Q2 2025 in Review

Opaleye Management sold out of Nurix Therapeutics (NRIX) in Q2 2025, closing a stake of 115,000 shares — an estimated $1.37M sold.

Opaleye Management first reported a position in NRIX in Q1 2024 and held it in 5 quarters. The position peaked at $9.44M in Q3 2024. 163 funds tracked by Wall St. Rank hold NRIX as of Q2 2025.

  • Opaleye Management reported no remaining Nurix Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Opaleye Management sold 115,000 Nurix Therapeutics shares in Q2 2025, an estimated $1.37M.
  • Opaleye Management first reported a position in Nurix Therapeutics in Q1 2024 and held it in 5 quarters.
  • Opaleye Management's Nurix Therapeutics position peaked at $9.44M in Q3 2024.
  • 163 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2025.

Based on Opaleye Management's 13F filing for Q2 2025, filed 14 Aug 2025.